...to radio/chemotherapy (TEDAC) Erytech Pharma S.A. (Euronext:ERYP); ExonHit S.A. (Euronext:ALEHT); InGen BioSciences Group (now part of ExonHit...

...development as their main business. Ark Therapeutics Group plc is now a manufacturing services provider; ExonHit S.A....

...$27.1M undisclosed round Oct 2002 - reverse-merged with SWX-listed Askilia Holding Diaxonhit (Euronext:ALEHT) (formerly ExonHit Therapeutics...

...Daixonhit, will continue to trade on Euronext under the symbol "ALEHT" (see BioCentury, Nov. 12). ExonHit S.A....

...in cash and issue €10 million ($12.8 million) in new ExonHit shares to InGen shareholders. ExonHit...
...to the acquisition. Additionally, for each ExonHit share held at a Dec. 14 general meeting, ExonHit...
...The deal, which is subject to ExonHit shareholder approval, is expected to close Dec. 19. ExonHit S.A....

...effects. At least one other PDE-4B inhibitor is in development for neurological indications. In 2009, ExonHit S.A....
...primary safety endpoint in a Phase IIa trial in patients with mild to moderate AD. ExonHit...
...Business Technology Transfer (STTR) funding to evaluate Tetra's compounds in TBI. Companies and Institutions Mentioned ExonHit S.A....

...DIALOG trial evaluating AclarusDx. The product has CE Mark approval and is available in France. ExonHit S.A....

...pilot trial evaluating AclarusDx. The product has CE Mark approval and is available in France. ExonHit S.A....